Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges?

Two drug therapy options—semaglutide (s.c.) and resmetirom (oral)—are now approved in the EU and the U.S. for the treatment of MASH. This is a major breakthrough, especially since, for a long time, no drug therapies specifically approved for the indication of steatotic liver disease were available. The ESSENCE and MAESTRO-NASH studies were pivotal. In addition, an ESSENCE and MAESTRO-NASH study on survodutide is currently underway, and many other clinical trials are planned or already in progress. During a panel discussion, international experts discussed the key challenges and goals of current research efforts.